A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment

Oncology Reports

Volumn 33, Issue 4, 2015, Pages 1585-1592

  Fujio, Kei ^a   Watanabe, Masami ^a,b   Ueki, Hideo ^a   Li, Shun Ai ^a,b   Kinoshita, Rie ^a   Ochiai, Kazuhiko ^c   Futami, Junichiro ^a   Watanabe, Toyohiko ^a   Nasu, Yasutomo ^a,b   Kumon, Hiromi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c NIPPON VETERINARY AND LIFE SCIENCE UNIVERSITY   (Japan)

Author keywords

Cytokine; Fusion protein; Prostate cancer; Prostatic acid phosphatase; Vaccine

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 7; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT PROTEIN; ACID PHOSPHATASE; CANCER VACCINE; INTERLEUKIN DERIVATIVE; SYNTHETIC DNA; TUMOR ANTIGEN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER MODEL; CELL DIFFERENTIATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG ACTIVITY; DRUG DEVELOPMENT; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MONOCYTE; MOUSE; MOUSE MODEL; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SYNTHESIS; UPREGULATION; VALIDATION PROCESS; ACTIVE IMMUNOTHERAPY; ADENOCARCINOMA; ANIMAL; C57BL MOUSE; CELL CULTURE; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PATHOLOGY; PLASMID; PROSTATIC NEOPLASMS;

ACID PHOSPHATASE; ADENOCARCINOMA; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL DIFFERENTIATION; CELLS, CULTURED; DENDRITIC CELLS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; GENE EXPRESSION; GENES, SYNTHETIC; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY, ACTIVE; INTERLEUKINS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MONOCYTES; PLASMIDS; PROSTATIC NEOPLASMS; RECOMBINANT FUSION PROTEINS;

EID: 84924860290     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3770     Document Type: Article

References (36)

1. Fong L, Ruegg CL, Brockstedt D, Engleman EG and Laus R: Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol 159: 3113-3117, 1997.
2. Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL and Engleman EG: Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 167: 7150-7156, 2001.
3. Roos AK, Pavlenko M, Charo J, Egevad L and Pisa P: Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. Prostate 15: 217-223, 2005.
4. Saha A, Chatterjee SK, Mohanty K, Foon KA and Bhattacharya-Chatterjee M: Dendritic cell based vaccines for immunotherapy of cancer. Cancer Ther 1: 299-314, 2003.
5. Matera L: The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer. Cancer Treat Rev 36: 131-141, 2010.
6. Drake CG: Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 10: 580-593, 2010.
7. Watanabe M, Nasu Y and Kumon H: Adenovirus-mediated REIC/Dkk-3 gene therapy: Development of an autologous cancer vaccination therapy (Review). Oncol Lett 7: 595-601, 2014.
8. Saif JM, Vadakekolathu J, Rane SS, McDonald D, Ahmad M, Mathieu M, Pockley AG, Durrant L, Metheringham R, Rees RC and McArdle SE: Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice. Eur J Immunol 44: 994-1004, 2014.
9. Peshwa MV, Shi JD, Ruegg C, Laus R and van Schooten WC: Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 36: 129-138, 1998.
10. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422, 2010.
11. Di Lorenzo G, Ferro M and Buonerba C: Sipuleucel-T (Provenge®) for castration-resistant prostate cancer. BJU Int 110: E99-E104, 2012.
12. McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC and Wilding G: Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 27: 4047-4054, 2009.
13. Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E and Eisenbach L: Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res 65: 6435-6442, 2005.
14. Matsueda S, Takedatsu H, Yao A, Tanaka M, Noguchi M, Itoh K and Harada M: Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles. Clin Cancer Res 11: 6933-6943, 2005.
15. Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, Padley DJ, Peshwa MV, Pitot HC, Richardson RL, Smits BJ, Sopapan P, Strang G, Valone FH and Vuk-Pavlovi S: Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 6: 2175-2182, 2000.
16. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV and Valone FH: Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18: 3894-3903, 2000.
17. Zou GM and Tam YK: Cytokines in the generation and maturation of dendritic cells: recent advances. Eur Cytokine Netw 13: 186-199, 2002.
18. Liao W, Lin JX and Leonard WJ: IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol 23: 598-604, 2011.
19. Marçais A, Viel S, Grau M, Henry T, Marvel J and Walzer T: Regulation of mouse NK cell development and function by cytokines. Front Immunol 4: 450, 2013.
20. Watanabe M, Sakaguchi M, Kinoshita R, Kaku H, Ariyoshi Y, Ueki H, Tanimoto R, Ebara S, Ochiai K, Futami J, Li SA, Huang P, Nasu Y, Huh NH and Kumon H: A novel gene expression system strongly enhances the anticancer effects of a REIC/Dkk-3-encoding adenoviral vector. Oncol Rep 31: 1089-1095, 2014.
21. Sakaguchi M, Watanabe M, Kinoshita R, Kaku H, Ueki H, Futami J, Murata H, Inoue Y, Li SA, Huang P, Putranto EW, Ruma IM, Nasu Y, Kumon H and Huh NH: Dramatic increase in expression of a transgene by insertion of promoters downstream of the cargo gene. Mol Biotechnol 56: 621-630, 2014.
22. Watanabe M, Kashiwakura Y, Huang P, Ochiai K, Futami J, Li SA, Takaoka M, Nasu Y, Sakaguchi M, Huh NH and Kumon H: Immunological aspects of REIC/Dkk-3 in monocyte differentiation and tumor regression. Int J Oncol 34: 657-663, 2009.
23. Kitamura T, Tojo A, Kuwaki T, Chiba S, Miyazono K, Urabe A and Takaku F: Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1. Blood 73: 375-380, 1989.
24. Klampfer L, Zhang J and Nimer SD: GM-CSF rescues TF-1 cells from growth factor withdrawal-induced, but not differentiationinduced apoptosis: the role of BCL-2 and MCL-1. Cytokine 11: 849-855, 1999.
25. Lu X, Park SH, Thompson TC and Lane DP: ras-Induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell 70: 153-161, 1992.
26. Chen J, Watanabe M, Huang P, Sakaguchi M, Ochiai K, Nasu Y, Ouchida M, Huh NH, Shimizu K, Kashiwakura Y, Kaku H and Kumon H: REIC/Dkk-3 stable transfection reduces the malignant phenotype of mouse prostate cancer RM9 cells. Int J Mol Med 24: 789-794, 2009.
27. Charley B, Petit E, Leclerc C and Stefanos S: Production of porcine interleukin-2 and its biological and antigenic relationships with human interleukin-2. Immunol Lett 10: 121-126, 1985.
28. Chazen GD, Pereira GM, LeGros G, Gillis S and Shevach EM: Interleukin 7 is a T-cell growth factor. Proc Natl Acad Sci USA 86: 5923-5927, 1989.
29. Barata JT, Silva A, Abecasis M, Carlesso N, Cumano A and Cardoso AA: Molecular and functional evidence for activity of murine IL-7 on human lymphocytes. Exp Hematol 34: 1133-1142, 2006.
30. Kradin RL, Xia W, Pike M, Byers HR and Pinto C: Interleukin-2 promotes the motility of dendritic cells and their accumulation in lung and skin. Pathobiology 64: 180-186, 1996.
31. Bykovskaja SN, Buffo MJ, Bunker M, Zhang H, Majors A, Herbert M, Lokshin A, Levitt ML, Jaja A, Scalise D, Kosiban D, Evans C, Marks S and Shogan J: Interleukin-2 induces development of denditric cells from cord blood CD34+ cells. J Leukoc Biol 63: 620-630, 1998.
32. Civallero M, Barni S, Nano R and Capelli E: Dendritic cells and interleukin-2: cytochemical and ultrastructural study. Histol Histopathol 15: 1077-1085, 2000.
33. Lynch DH, Namen AE and Miller RE: In vivo evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti-tumor cytotoxic T lymphocytes. Eur J Immunol 21: 2977-2985, 1991.
34. Mackensen A, Lindemann A and Mertelsmann R: Immunostimulatory cytokines in somatic cells and gene therapy of cancer. Cytokine Growth Factor Rev 8: 119-128, 1997.
35. Sakaguchi M, Kataoka K, Abarzua F, Tanimoto R, Watanabe M, Murata H, Than SS, Kurose K, Kashiwakura Y, Ochiai K, Nasu Y, Kumon H and Huh NH: Overexpression of REIC/Dkk-3 in normal fibroblasts suppresses tumor growth via induction of interleukin-7. J Biol Chem 284: 14236-14244, 2009.
36. Iwamoto H, Ojima T, Hayata K, Katsuda M, Miyazawa M, Iida T, Nakamura M, Nakamori M, Iwahashi M and Yamaue H: Antitumor immune response of dendritic cells (DCs) expressing tumor-associated antigens derived from induced pluripotent stem cells: in comparison to bone marrow-derived DCs. Int J Cancer 134: 332-341, 2014.